745 related articles for article (PubMed ID: 21827413)
21. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
[TBL] [Abstract][Full Text] [Related]
22. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
Hu J; Muller KA; Furnari FB; Cavenee WK; VandenBerg SR; Gonias SL
Oncogene; 2015 Jul; 34(31):4078-88. PubMed ID: 25347738
[TBL] [Abstract][Full Text] [Related]
23. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
24. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
25. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
26. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
[TBL] [Abstract][Full Text] [Related]
27. HER1/EGFR targeting: refining the strategy.
Pérez-Soler R
Oncologist; 2004; 9(1):58-67. PubMed ID: 14755015
[TBL] [Abstract][Full Text] [Related]
28. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.
Guo G; Gong K; Ali S; Ali N; Shallwani S; Hatanpaa KJ; Pan E; Mickey B; Burma S; Wang DH; Kesari S; Sarkaria JN; Zhao D; Habib AA
Nat Neurosci; 2017 Aug; 20(8):1074-1084. PubMed ID: 28604685
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
Dhomen NS; Mariadason J; Tebbutt N; Scott AM
Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
[TBL] [Abstract][Full Text] [Related]
30. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
31. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.
Lo HW
Curr Mol Pharmacol; 2010 Jan; 3(1):37-52. PubMed ID: 20030624
[TBL] [Abstract][Full Text] [Related]
32. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
[TBL] [Abstract][Full Text] [Related]
33. Targeting the epidermal growth factor receptor in high-grade astrocytomas.
Voelzke WR; Petty WJ; Lesser GJ
Curr Treat Options Oncol; 2008 Feb; 9(1):23-31. PubMed ID: 18247132
[TBL] [Abstract][Full Text] [Related]
34. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
[TBL] [Abstract][Full Text] [Related]
35. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Yoshida Y; Ozawa T; Yao TW; Shen W; Brown D; Parsa AT; Raizer JJ; Cheng SY; Stegh AH; Mazar AP; Giles FJ; Sarkaria JN; Butowski N; Nicolaides T; James CD
Mol Cancer Ther; 2014 Dec; 13(12):2919-29. PubMed ID: 25313012
[TBL] [Abstract][Full Text] [Related]
36. PTPIP51 levels in glioblastoma cells depend on inhibition of the EGF-receptor.
Petri MK; Brobeil A; Planz J; Bräuninger A; Gattenlöhner S; Nestler U; Stenzinger A; Paradowska A; Wimmer M
J Neurooncol; 2015 May; 123(1):15-25. PubMed ID: 25862004
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of resistance to HER family targeting antibodies.
Kruser TJ; Wheeler DL
Exp Cell Res; 2010 Apr; 316(7):1083-100. PubMed ID: 20064507
[TBL] [Abstract][Full Text] [Related]
38. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
39. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
40. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Li X; Wu C; Chen N; Gu H; Yen A; Cao L; Wang E; Wang L
Oncotarget; 2016 May; 7(22):33440-50. PubMed ID: 26967052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]